| scholarly article | Q13442814 |
| P2093 | author name string | B Matija Peterlin | |
| Xin Lin | |||
| T S Benedict Yen | |||
| Laurence Huang | |||
| Dan Irwin | |||
| Satoshi Kanazawa | |||
| Joseph Romeo | |||
| P2860 | cites work | DSIF, a novel transcription elongation factor that regulates RNA polymerase II processivity, is composed of human Spt4 and Spt5 homologs | Q24328838 |
| CDK9 autophosphorylation regulates high-affinity binding of the human immunodeficiency virus type 1 tat-P-TEFb complex to TAR RNA | Q24550765 | ||
| The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein | Q24680024 | ||
| 7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes | Q28116607 | ||
| NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation | Q28141291 | ||
| Molecular mechanism of decreased glutathione content in human immunodeficiency virus type 1 Tat-transgenic mice | Q28143660 | ||
| The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription | Q28206012 | ||
| The challenge of viral reservoirs in HIV-1 infection | Q28216956 | ||
| Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy | Q28253761 | ||
| A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA | Q28263974 | ||
| The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation | Q28361880 | ||
| Reversible phosphorylation of the C-terminal domain of RNA polymerase II | Q29614790 | ||
| Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product | Q29615049 | ||
| Immune Hyperactivation of HIV-1-Infected T Cells Mediated by Tat and the CD28 Pathway | Q63351477 | ||
| Recovery of AIDS-associated retroviruses from patients with AIDS or AIDS-related conditions and from clinically healthy individuals | Q68943219 | ||
| Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy | Q77890124 | ||
| In vivo protein transduction: delivery of a biologically active protein into the mouse | Q29615482 | ||
| Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy | Q29615993 | ||
| Recovery of replication-competent HIV despite prolonged suppression of plasma viremia | Q29615995 | ||
| An inducible transcription factor activates expression of human immunodeficiency virus in T cells | Q29618434 | ||
| HIV-1 integration in the human genome favors active genes and local hotspots | Q29618457 | ||
| Control of RNA initiation and elongation at the HIV-1 promoter | Q29620157 | ||
| P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II | Q29620167 | ||
| Cellular uptake of the tat protein from human immunodeficiency virus | Q29620627 | ||
| HIV-1 Tat protein trans-activates transcription in vitro | Q30411837 | ||
| Tat-associated kinase, TAK, activity is regulated by distinct mechanisms in peripheral blood lymphocytes and promonocytic cell lines | Q33786066 | ||
| Human immunodeficiency virus long terminal repeat responds to T-cell activation signals | Q34350307 | ||
| Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency | Q34362915 | ||
| A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team | Q34438252 | ||
| Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein | Q34556566 | ||
| Cellular latency in human immunodeficiency virus-infected individuals with high CD4 levels can be detected by the presence of promoter-proximal transcripts | Q35202038 | ||
| The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein | Q35211232 | ||
| Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. | Q36011366 | ||
| Bidirectional activity of the rat insulin II 5'-flanking region in transgenic mice | Q36833124 | ||
| Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines | Q36851755 | ||
| Standardization of sensitive human immunodeficiency virus coculture procedures and establishment of a multicenter quality assurance program for the AIDS Clinical Trials Group. The NIH/NIAID/DAIDS/ACTG Virology Laboratories | Q37123606 | ||
| The ability of positive transcription elongation factor B to transactivate human immunodeficiency virus transcription depends on a functional kinase domain, cyclin T1, and Tat. | Q39580108 | ||
| Optimized chimeras between kinase-inactive mutant Cdk9 and truncated cyclin T1 proteins efficiently inhibit Tat transactivation and human immunodeficiency virus gene expression | Q39685303 | ||
| A minimal chimera of human cyclin T1 and tat binds TAR and activates human immunodeficiency virus transcription in murine cells. | Q39685470 | ||
| Genetic analysis of the cofactor requirement for human immunodeficiency virus type 1 Tat function. | Q40045693 | ||
| Secretion of glycosylation site mutants can be rescued by the signal/pro sequence of tissue plasminogen activator | Q40921091 | ||
| Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. | Q40990135 | ||
| The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. | Q41247263 | ||
| Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. | Q41335848 | ||
| Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein | Q41349382 | ||
| Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients | Q41734588 | ||
| Abnormal glucose handling by the kidney in response to hypoglycemia in type 1 diabetes | Q43719971 | ||
| NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. | Q43730164 | ||
| Recombination: Multiply infected spleen cells in HIV patients | Q43923409 | ||
| Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy | Q44196959 | ||
| Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency | Q44325918 | ||
| Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of class II MHC and interferon-gamma | Q44506225 | ||
| Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy | Q45760702 | ||
| Neurotoxicity of peptide analogues of the transactivating protein tat from Maedi-Visna virus and human immunodeficiency virus | Q45787004 | ||
| Expression and characterization of the trans-activator of HTLV-III/LAV virus | Q45831293 | ||
| In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. | Q52050894 | ||
| Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs. | Q52078801 | ||
| Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. | Q53437454 | ||
| Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia | Q57075698 | ||
| Cell-specific expression controlled by the 5′-flanking region of insulin and chymotrypsin genes | Q59057041 | ||
| The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice | Q59060595 | ||
| Diabetes in transgenic mice resulting from over-expression of class I histocompatibility molecules in pancreatic β cells | Q59073388 | ||
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 8227-8236 | |
| P577 | publication date | 2003-08-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Transcriptional profiles of latent human immunodeficiency virus in infected individuals: effects of Tat on the host and reservoir | |
| P478 | volume | 77 |
| Q36038655 | A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals |
| Q35400385 | A hardwired HIV latency program |
| Q24804709 | A new paradigm in eukaryotic biology: HIV Tat and the control of transcriptional elongation |
| Q37348552 | Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo |
| Q35088292 | Analysis of multiply spliced transcripts in lymphoid tissue reservoirs of rhesus macaques infected with RT-SHIV during HAART |
| Q92906228 | Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease |
| Q40391119 | Assays for precise quantification of total (including short) and elongated HIV-1 transcripts. |
| Q47600035 | Assays to Measure Latency, Reservoirs, and Reactivation |
| Q90594756 | Barriers for HIV Cure: The Latent Reservoir |
| Q42573954 | CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency |
| Q40375877 | Cell-dependent interference of a series of new 6-aminoquinolone derivatives with viral (HIV/CMV) transactivation |
| Q30401785 | Cellular heterogeneity and live cell arrays |
| Q42059823 | Chromatin reassembly factors are involved in transcriptional interference promoting HIV latency |
| Q33877492 | Combinatorial latency reactivation for HIV-1 subtypes and variants |
| Q33398516 | Control of stochastic gene expression by host factors at the HIV promoter |
| Q33495565 | CpG methylation controls reactivation of HIV from latency |
| Q42230600 | Disruption of polycomb repressor complex-mediated gene silencing reactivates HIV-1 provirus in latently infected cells |
| Q47432196 | Dose-dependent neurocognitive deficits following postnatal day 10 HIV-1 viral protein exposure: Relationship to hippocampal anatomy parameters. |
| Q28646726 | Dynamics of human immunodeficiency virus transcription: P-TEFb phosphorylates RD and dissociates negative effectors from the transactivation response element |
| Q52606459 | Exosomal Tat protein activates latent HIV-1 in primary, resting CD4+ T lymphocytes. |
| Q36708954 | Experimental approaches to the study of HIV-1 latency |
| Q38119498 | Feline immunodeficiency virus latency. |
| Q42153205 | Fluctuations in Tat copy number when it counts the most: a possible mechanism to battle the HIV latency |
| Q47149126 | Functional Studies of CCAAT/Enhancer Binding Protein Site Located Downstream of the Transcriptional Start Site. |
| Q52680785 | HIV latency in isolated patient CD4+ T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing. |
| Q40361663 | HIV latency: present knowledge, future directions |
| Q33292464 | HIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTR |
| Q39134277 | HIV-1 Tat and Viral Latency: What We Can Learn from Naturally Occurring Sequence Variations. |
| Q36515071 | HIV-specific CD8⁺ T cells and HIV eradication |
| Q45395775 | Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells |
| Q34664366 | Human immunodeficiency virus-1 (HIV-1)-mediated apoptosis: new therapeutic targets |
| Q33425135 | Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation |
| Q35761152 | Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity |
| Q37724091 | Lessons learned from HIV vaccine clinical efficacy trials |
| Q40503301 | Leucine culture reveals that ATP synthase functions as a fuel sensor in pancreatic beta-cells |
| Q36109980 | Morphine efficacy is altered in conditional HIV-1 Tat transgenic mice. |
| Q40180319 | Novel in vivo model for the study of human immunodeficiency virus type 1 transcription inhibitors: evaluation of new 6-desfluoroquinolone derivatives |
| Q33250088 | Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells |
| Q42093067 | Primary cell model for activation-inducible human immunodeficiency virus |
| Q24548940 | Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells |
| Q40210146 | Sequential modifications in class II transactivator isoform 1 induced by lipopolysaccharide stimulate major histocompatibility complex class II transcription in macrophages |
| Q37549111 | Stochastic gene expression as a molecular switch for viral latency |
| Q38212101 | Strategies to Block HIV Transcription: Focus on Small Molecule Tat Inhibitors |
| Q42100247 | Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency |
| Q36605014 | Synaptic dysfunction in the hippocampus accompanies learning and memory deficits in human immunodeficiency virus type-1 Tat transgenic mice. |
| Q64107839 | Tat inhibition by didehydro-Cortistatin A promotes heterochromatin formation at the HIV-1 long terminal repeat |
| Q24519068 | Tetraspanin CD81 provides a costimulatory signal resulting in increased human immunodeficiency virus type 1 gene expression in primary CD4+ T lymphocytes through NF-kappaB, NFAT, and AP-1 transduction pathways |
| Q38887465 | The Latent Reservoir for HIV-1: How Immunologic Memory and Clonal Expansion Contribute to HIV-1 Persistence |
| Q28476094 | Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART |
| Q50642600 | Transient-mediated fate determination in a transcriptional circuit of HIV. |
| Q36857114 | Treatment implications of the latent reservoir for HIV-1. |
Search more.